HMO Infant Formula Modulating GABAergic Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to improve cognitive functions, particularly GABAergic functions, in infants and young children to support neurodevelopment and prevent disorders such as attention deficit/hyperactivity disorders, autism spectrum disorders, and schizophrenia. Current infant formulas lack essential nutrients found in breast milk that promote optimal cognitive development.
Innovation Solution
The administration of specific oligosaccharides, including human milk oligosaccharides (HMO), bovine milk oligosaccharides (BMOS), and fructo-oligosaccharides (FOS), in combination with probiotics, to enhance GABAergic function in the central nervous system (CNS). These oligosaccharides are incorporated into nutritional compositions such as infant formulas to promote filtering of information and focus in young subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional infant formulas are used, then basic nutritional requirements are met, but cognitive development and GABAergic functions are not optimally supported
Solution Approach 1:
The patent employs composite materials by combining multiple types of oligosaccharides (HMO, BMOS, FOS) with probiotics and other nutritional components in a synergistic formula. This composite approach enhances GABAergic function and cognitive development support more effectively than single-component formulations, directly resolving the contradiction between improved reliability of cognitive support and manufacturing complexity.
Solution Approach 2:
The patent applies parameter changes by systematically varying the concentrations and combinations of different oligosaccharide types and probiotic strains in the formula. By optimizing these parameters, the formulation achieves enhanced GABAergic function support while maintaining manageable manufacturing complexity through standardized production processes.
2Reliability
If human milk oligosaccharides are added to infant formula, then GABAergic function is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent merges multiple beneficial components (HMO, BMOS, FOS, and probiotics) into a single integrated formula system. This combining approach enhances GABAergic function through synergistic interactions while managing composition complexity by establishing a unified formulation framework that simplifies manufacturing processes.
Solution Approach 2:
The patent applies multi-functionality by designing a universal formula base that can be adapted for different infant age groups and developmental stages. The core formulation with multiple oligosaccharide types and probiotics provides broad-spectrum GABAergic support across various populations, reducing the need for multiple specialized formulations and thereby managing complexity.
3Reliability
If multiple types of oligosaccharides are combined, then cognitive development is optimized, but production cost increases
Solution Approach 1:
The patent applies local quality by strategically distributing different types of oligosaccharides to specific functional targets within the gut-brain axis. Each oligosaccharide type is positioned to address specific developmental needs, optimizing cognitive development support while controlling total substance quantity through precise formulation ratios that maximize efficacy per unit.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the concentration ratios and compositional parameters of different oligosaccharide types to achieve maximum cognitive development support at minimal total substance levels. This parameter optimization balances the quantity of substances required with the desired functional outcomes, managing production costs while maintaining high reliability of developmental support.
Data Source
AI summary
The invention relates to a nutritional composition comprising human milk oligosaccharide (HMO) having an effect on in a mammal to improve, enhance, promote or modulate a GABAergic function in the CNS, preferably in a human infant or a young children between birth and 7 years. The composition can be an infant formula. The HMO may be 2FL, diFL and/or LNT and or LNnT or combinations thereof.